PRQR vs. ORIC, SVRA, CYRX, CDMO, IGMS, TRDA, SIGA, YMAB, OLMA, and TVTX
Should you be buying ProQR Therapeutics stock or one of its competitors? The main competitors of ProQR Therapeutics include ORIC Pharmaceuticals (ORIC), Savara (SVRA), Cryoport (CYRX), Avid Bioservices (CDMO), IGM Biosciences (IGMS), Entrada Therapeutics (TRDA), SIGA Technologies (SIGA), Y-mAbs Therapeutics (YMAB), Olema Pharmaceuticals (OLMA), and Travere Therapeutics (TVTX). These companies are all part of the "pharmaceutical preparations" industry.
ProQR Therapeutics (NASDAQ:PRQR) and ORIC Pharmaceuticals (NASDAQ:ORIC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, community ranking, institutional ownership and profitability.
ORIC Pharmaceuticals has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -260.75%. ORIC Pharmaceuticals' return on equity of -38.08% beat ProQR Therapeutics' return on equity.
ProQR Therapeutics received 279 more outperform votes than ORIC Pharmaceuticals when rated by MarketBeat users. However, 66.20% of users gave ORIC Pharmaceuticals an outperform vote while only 61.86% of users gave ProQR Therapeutics an outperform vote.
ProQR Therapeutics has higher revenue and earnings than ORIC Pharmaceuticals. ProQR Therapeutics is trading at a lower price-to-earnings ratio than ORIC Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
ProQR Therapeutics has a beta of 0.3, meaning that its share price is 70% less volatile than the S&P 500. Comparatively, ORIC Pharmaceuticals has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500.
In the previous week, ORIC Pharmaceuticals had 3 more articles in the media than ProQR Therapeutics. MarketBeat recorded 6 mentions for ORIC Pharmaceuticals and 3 mentions for ProQR Therapeutics. ProQR Therapeutics' average media sentiment score of 1.45 beat ORIC Pharmaceuticals' score of 0.80 indicating that ProQR Therapeutics is being referred to more favorably in the media.
32.7% of ProQR Therapeutics shares are held by institutional investors. Comparatively, 95.1% of ORIC Pharmaceuticals shares are held by institutional investors. 8.4% of ProQR Therapeutics shares are held by company insiders. Comparatively, 5.6% of ORIC Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
ProQR Therapeutics presently has a consensus price target of $3.38, indicating a potential upside of 84.43%. ORIC Pharmaceuticals has a consensus price target of $20.00, indicating a potential upside of 136.69%. Given ORIC Pharmaceuticals' higher probable upside, analysts clearly believe ORIC Pharmaceuticals is more favorable than ProQR Therapeutics.
Summary
ORIC Pharmaceuticals beats ProQR Therapeutics on 9 of the 16 factors compared between the two stocks.
Get ProQR Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRQR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ProQR Therapeutics Competitors List
Related Companies and Tools
